|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1650 Diagonal Road |
Address2 |
|
| City | ALEXANDRIA |
State | VA |
Zip Code | 22314 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 1386-12
|
||||||||
|
6. House ID# 321810000
|
||||||||
| TYPE OF REPORT | 8. Year | 2023 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Jonah Scharf |
Date | 10/20/2023 10:59:26 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
August 17, 2023 letter to CMS Administrator Chiquita Brooks-LaSure in response to the agency's Request for Information on Episode-Based Payment Models expressing support for the agency's broad goal of providing enhanced patient care in the context of value-based reimbursement arrangements.
August 30, 2023 comment letter regarding the Food and Drug Administration's Center for Devices and Radiological Healths (CDRH) search for input from the physician community on advancing health equity and facilitating access to medical devices designed to be safe and effective when used outside of traditional clinical settings such as the home setting.
September 11, 2023 letter to CMS Administrator Chiquita Brooks-LaSure in response to the calendar year 2024 Medicare Physician Fee Schedule and Quality Payment Program proposed rule.
September 11, 2023 letter to CMS Administrator Chiquita Brooks-LaSure pertaining to the ambulatory surgical center payment update and updated APC classifications for various HCPCS codes.
September 28, 2023 coalition letter to Representative Lisa Blunt Rochester and Representative Brian Fitzpatrick in support of H.R. 4775, the Helping Tobacco Users Quit Act, that will ensure that all Medicaid and Childrens Health Insurance Program enrollees have access to the full array of evidence-based tobacco cessation treatments, including all Food and Drug Administration medications.
Issues pertaining to scope of practice legislation specifically related to opposition of S. 2377, the Medicare Audiology Access Improvement Act of 2023, and in general.
Issues related to the support of the Safe Step Act (S. 652 / H.R. 2630) which would improve patient access by requiring insurance providers to implement a clear and transparent process for a patient or physician to request an exception to a step therapy protocol.
Issues pertaining to prior authorization, in general.
Issues pertaining to Medicare physician reimbursement related to H.R. 2474, the Strengthening Medicare for Patients and Providers Act, and in general.
Issues related to hearing healthcare, in general.
Issues pertaining to the implementation of the No Surprises Act.
Issues pertaining to health information technology and electronic health records, in general.
Issues pertaining to Graduate Medical Education, in general.
Issues pertaining to healthcare liability reform, in general.
Issues pertaining to healthcare practice and the Federal Supremacy Clause at the Department of Veterans Affairs, in general.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), Federal Trade Commission (FTC), Centers For Medicare and Medicaid Services (CMS), Health Resources & Services Administration (HRSA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maura |
Farrell |
|
|
|
John |
Aguilar |
|
|
|
Harry |
DeCabo |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
August 17, 2023 letter to CMS Administrator Chiquita Brooks-LaSure in response to the agency's Request for Information on Episode-Based Payment Models expressing support for the agency's broad goal of providing enhanced patient care in the context of value-based reimbursement arrangements.
September 11, 2023 letter to CMS Administrator Chiquita Brooks-LaSure in response to the calendar year 2024 Medicare Physician Fee Schedule and Quality Payment Program proposed rule.
September 11, 2023 letter to CMS Administrator Chiquita Brooks-LaSure pertaining to the ambulatory surgical center payment update and updated APC classifications for various HCPCS codes.
September 28, 2023 coalition letter to Representative Lisa Blunt Rochester and Representative Brian Fitzpatrick in support of H.R. 4775, the Helping Tobacco Users Quit Act, that will ensure that all Medicaid and Childrens Health Insurance Program enrollees have access to the full array of evidence-based tobacco cessation treatments, including all Food and Drug Administration medications.
Issues pertaining to scope of practice legislation specifically related to opposition of S. 2377, the Medicare Audiology Access Improvement Act of 2023, and in general.
Issues pertaining to prior authorization, in general.
Issues pertaining to Medicare physician reimbursement, related to H.R. 2474, the Strengthening Medicare for Patients and Providers Act, and in general.
Issues related to hearing healthcare, in general.
Issues pertaining to health information technology and electronic health records, in general.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maura |
Farrell |
|
|
|
John |
Aguilar |
|
|
|
Harry |
DeCabo |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TOB
16. Specific lobbying issues
September 28, 2023 coalition letter to Representative Lisa Blunt Rochester and Representative Brian Fitzpatrick in support of H.R. 4775, the Helping Tobacco Users Quit Act, that will ensure that all Medicaid and Childrens Health Insurance Program enrollees have access to the full array of evidence-based tobacco cessation treatments, including all Food and Drug Administration medications.
Issues pertaining to tobacco control, in general.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maura |
Farrell |
|
|
|
John |
Aguilar |
|
|
|
Harry |
DeCabo |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
Issues pertaining to healthcare practice and the Federal Supremacy Clause at the Department of Veterans Affairs, in general.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maura |
Farrell |
|
|
|
John |
Aguilar |
|
|
|
Harry |
DeCabo |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Issues pertaining to the budget and appropriations, in general.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Maura |
Farrell |
|
|
|
John |
Aguilar |
|
|
|
Harry |
DeCabo |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |